Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Associations between physical activity and sociodemographic and migration-related correlates among adults with a history of migration in Germany: results of a nationwide cross-sectional survey.

BMC public health·2026
Same author

Dilution displacement enabled measurement of total ligand levels in the presence of an anti-ligand antibody using LBA.

Bioanalysis·2026
Same author

Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma.

Research (Washington, D.C.)·2026
Same author

Electrically functionalized body surface for deep-tissue bioelectrical recording.

Nature biomedical engineering·2026
Same author

Photoaged microplastics disrupt endothelial stretch-sensitive ion channels to impair calcium signaling and vascular integrity.

bioRxiv : the preprint server for biology·2026
Same author

Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

相关实验视频

Updated: Sep 9, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K

通过CD70导向的异性CAR-NKT细胞对转移性瘤进行多式向

Yan-Ruide Li1, Junhui Hu2, Zhe Li1

  • 1Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Bioengineering, UCLA, Los Angeles, CA 90095, USA.

Cell reports. Medicine
|August 30, 2025
PubMed
概括
此摘要是机器生成的。

研究人员开发了针对转移性细胞癌 (RCC) 的新型CAR- NKT细胞. 这种现成的免疫疗法可针对双重瘤和微环境,

关键词:
一个CAR-NKT单元CD70 其他在HSPCNKT 细胞其他一个RCC细胞癌美国全活性T细胞所有的拒绝造血干细胞和原始细胞不变的自然杀手T细胞多模式定位来自患者的异种移植模型瘤微环境

更多相关视频

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K

相关实验视频

Last Updated: Sep 9, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K

科学领域:

  • 免疫疗法
  • 癌症学
  • 细胞治疗

背景情况:

  • 细胞癌 (RCC) 占癌的90%.
  • 尽管目前的治疗方法,但在30%-40%的患者中发生转移性疾病.
  • 现有的仿真抗原受体 (CAR) -T疗法面临着自主,个性化的方法的挑战.

研究的目的:

  • 为转移性RCC开发一种全源,现成的免疫疗法.
  • 设计针对CD70的CAR-NKT自然杀手细胞.
  • 评估这些工程细胞的有效性和机制.

主要方法:

  • 血造干细胞和原始细胞被用来产生异性CD70导向的CAR工程不变的自然杀手T细胞 (ALLO-CAR70-NKT).
  • 用临床指导的培养方法实现了强大的扩张和高纯度.
  • 评估了对原发性和转移性RCC的细胞毒性,瘤微环境 (TME) 的向性和全反应性T细胞的消除.

主要成果:

  • 艾洛CAR70-NKT细胞表现出强大的扩张, 纯度高, 没有兄弟杀伤.
  • 这些细胞通过CAR和自然杀手 (NK) 受体介导的机制对RCC表现出强烈的细胞毒性.
  • 通过T细胞受体 (TCR) 识别,Allo-CAR70-NKT细胞选择性地向免疫抑制的TME,并消除了CD70+宿主全活性T细胞,从而提高了持久性.

结论:

  • 艾洛CAR70-NKT细胞代表了转移性RCC的有希望的下一代免疫疗法.
  • 这种"现成"的疗法比自主疗法具有显著的优势.
  • 双重瘤和TME向,以及全活性T细胞清除,为治疗转移性癌提供了令人信服的策略.